Ranch Capital Advisors Inc. reduced its stake in shares of Johnson & Johnson (NYSE:JNJ – Free Report) by 66.3% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 3,671 shares of the company’s stock after selling 7,233 shares during the quarter. Ranch Capital Advisors Inc.’s holdings in Johnson & Johnson were worth $537,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Several other institutional investors also recently bought and sold shares of JNJ. AE Wealth Management LLC grew its holdings in Johnson & Johnson by 21.7% during the 2nd quarter. AE Wealth Management LLC now owns 321,514 shares of the company’s stock valued at $46,992,000 after buying an additional 57,335 shares in the last quarter. DCF Advisers LLC raised its stake in shares of Johnson & Johnson by 100.0% in the second quarter. DCF Advisers LLC now owns 3,000 shares of the company’s stock valued at $438,000 after acquiring an additional 1,500 shares during the period. Sprucegrove Investment Management Ltd. boosted its position in shares of Johnson & Johnson by 1.2% during the second quarter. Sprucegrove Investment Management Ltd. now owns 109,535 shares of the company’s stock valued at $16,010,000 after buying an additional 1,300 shares during the period. Bridges Investment Management Inc. boosted its holdings in Johnson & Johnson by 74.2% during the 2nd quarter. Bridges Investment Management Inc. now owns 86,997 shares of the company’s stock valued at $12,715,000 after acquiring an additional 37,054 shares during the period. Finally, Godshalk Welsh Capital Management Inc. grew its holdings in shares of Johnson & Johnson by 2.0% in the second quarter. Godshalk Welsh Capital Management Inc. now owns 12,446 shares of the company’s stock worth $1,819,000 after purchasing an additional 240 shares during the last quarter. 69.55% of the stock is owned by hedge funds and other institutional investors.
Insider Activity at Johnson & Johnson
In related news, VP Robert J. Decker sold 5,635 shares of Johnson & Johnson stock in a transaction on Friday, August 30th. The stock was sold at an average price of $165.06, for a total value of $930,113.10. Following the completion of the transaction, the vice president now directly owns 18,973 shares in the company, valued at $3,131,683.38. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Company insiders own 0.16% of the company’s stock.
Analyst Ratings Changes
Check Out Our Latest Report on JNJ
Johnson & Johnson Price Performance
Shares of Johnson & Johnson stock opened at $164.82 on Friday. The firm has a market cap of $396.67 billion, a PE ratio of 10.28, a P/E/G ratio of 2.71 and a beta of 0.53. Johnson & Johnson has a twelve month low of $143.13 and a twelve month high of $168.85. The business has a 50-day moving average price of $161.02 and a 200 day moving average price of $154.17. The company has a quick ratio of 0.85, a current ratio of 1.07 and a debt-to-equity ratio of 0.44.
Johnson & Johnson (NYSE:JNJ – Get Free Report) last announced its earnings results on Wednesday, July 17th. The company reported $2.82 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.71 by $0.11. The business had revenue of $22.45 billion for the quarter, compared to analyst estimates of $22.33 billion. Johnson & Johnson had a net margin of 46.34% and a return on equity of 36.60%. The company’s revenue for the quarter was up 4.3% compared to the same quarter last year. During the same quarter last year, the business earned $2.80 earnings per share. Sell-side analysts predict that Johnson & Johnson will post 10.02 earnings per share for the current fiscal year.
Johnson & Johnson Dividend Announcement
The firm also recently declared a quarterly dividend, which was paid on Tuesday, September 10th. Stockholders of record on Tuesday, August 27th were given a dividend of $1.24 per share. The ex-dividend date of this dividend was Tuesday, August 27th. This represents a $4.96 annualized dividend and a dividend yield of 3.01%. Johnson & Johnson’s dividend payout ratio is presently 30.92%.
About Johnson & Johnson
Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.
Featured Articles
- Five stocks we like better than Johnson & Johnson
- What Are Dividend Contenders? Investing in Dividend Contenders
- Autohome’s Dividend and Buyback Make It a Strong EV Play
- How to Use High Beta Stocks to Maximize Your Investing Profits
- Cracker Barrel Is at the Bottom of the Barrel: Time to Buy?
- NYSE Stocks Give Investors a Variety of Quality Options
- Why Shopify Stock Has Analysts Buzzing About Big Gains
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ – Free Report).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.